Mirvetuximab soravtansine-gynx conferred a 33% reduction in risk for death compared with chemotherapy for women with folate receptor alpha-positive platinum-resistant ovarian cancer, according to topline data from the agent’s manufacturer.Results of the phase 3 MIRASOL trial also showed a similar reduction in risk for disease progression or death and a higher objective response rate with